Highlights

  • Syntara Limited (ASX:SNT) reported further Phase 2 observations for SNT-4728 in October 2026.
  • SNT-9465 scarring study recruitment was expanded from 20 to 30 participants.
  • The company announced receipt of an AUD 4.7 million research and development tax incentive.
  • Top-line results from the expanded SNT-9465 study are expected in the first quarter of 2027.

Syntara Limited (ASX:SNT), a Sydney-based clinical-stage biotechnology company, is progressing several experimental treatments targeting blood disorders, fibrosis and neurological conditions. Its recent announcements include additional findings from the Phase 2 study of SNT-4728 and an expanded clinical programme for the topical treatment SNT-9465. These developments place trial design, evidence quality and research funding at the centre of the company’s near-term reporting.

At the time of writing on 19 October 2026, Syntara shares were trading at AUD 0.020, an increase of 5.26% during the day’s trading session.

Company Business

Syntara develops medicines using its expertise in amine oxidase chemistry and the biology of extracellular matrix dysfunction. Its clinical programmes address diseases in which abnormal tissue remodelling, scarring or inflammation may play a role. The company’s research and management activities are based in Sydney, while its drug-development activities include studies undertaken with clinical and research partners.

Amsulostat, also known as SNT-5505, is being investigated in haematological disorders including myelofibrosis and myelodysplastic syndrome. SNT-4728 is being studied in idiopathic REM sleep behaviour disorder, a condition associated with increased risk of neurodegenerative disease. The topical pan-lysyl oxidase inhibitors SNT-9465 and SNT-6302 form the company’s skin-scarring programme. These medicines remain investigational; clinical trial activity does not establish regulatory approval or commercial efficacy.

Recent Development

In early October 2026, Syntara announced further results from the Phase 2 study of SNT-4728 in idiopathic REM sleep behaviour disorder. The update adds to the company’s clinical evidence base, although conclusions about clinical benefit, longer-term disease progression and subsequent development will depend on full evaluation of the trial findings and any additional studies.

Separately, Syntara expanded its double-blind, placebo-controlled Phase 1b study of SNT-9465 in hypertrophic scars following sternotomy surgery. With recruitment of the initial 20-person cohort approaching completion, the company increased the planned enrolment to 30 participants and added The Skin Hospital in Sydney as a clinical site. The company explicitly stated that the expansion was not based on treatment-efficacy data because the trial remains blinded.

The company also provided an update on an investigator-initiated study of SNT-6302 in keloid scars. Six participants had completed 12 weeks of treatment, with further follow-up planned. Eight participants discontinued treatment following local skin reactions, while the preliminary assessment did not identify observable differences in scar-rating scores or stiffness at week 12. These observations illustrate why tolerability and clinical endpoints remain important in evaluating topical treatments.

Financial Performance and Sector Context

In September 2026, Syntara announced receipt of an AUD 4.7 million research and development tax incentive. The payment is relevant to the funding of clinical activity, but should not be confused with recurring product revenue. As a development-stage drug company, Syntara’s operations depend on research spending, external study arrangements and sufficient financial resources to support planned work.

The company lodged its FY26 annual report in late August 2026 and its June-quarter cash-flow report in July. These disclosures provide the financial reporting framework for assessing operating expenditure, available cash and capital needs. Biotechnology trial costs can vary with participant recruitment, clinical-site activity, study duration and the scope of laboratory analysis. Regulatory requirements and the availability of appropriate trial participants also influence development schedules.

Risks to Consider

Clinical uncertainty remains material: early-stage results may not be replicated in larger studies, and safety or tolerability findings can affect the future use of a candidate. SNT-9465 must still generate interpretable safety and exploratory activity results after the expanded recruitment. The SNT-6302 study has already reported discontinuations related to local reactions. Funding needs, trial completion timelines and regulatory review are further considerations for a business without an established commercial portfolio of these investigational medicines.

What to Watch Next

The expanded SNT-9465 study is scheduled to report top-line data in the first quarter of 2027. Investors may also monitor further detail from the SNT-4728 programme, subsequent updates on amsulostat studies, completion of SNT-6302 follow-up and periodic disclosures on cash expenditure. Whether the clinical programmes move to additional studies will depend on evidence, study design decisions and resources.

Key Insights

Syntara’s current developments centre on clinical evidence rather than product sales. The October updates concern a neurological study and an expanded skin-scarring trial, while the AUD 4.7 million tax incentive contributes to research funding. Subsequent reporting will clarify study outcomes, the scale of future development commitments and the company’s financing position.